Word

MOGANSHAN

Status

Registered

Status Code

700

Status Date

Tuesday, March 19, 2024

Serial Number

79344895

Registration Number

7330063

Registration Date

Tuesday, March 19, 2024

Mark Type

3000

Filing Date

Tuesday, June 14, 2022

Published for Opposition

Tuesday, January 2, 2024

Trademark Owner History

Zhejiang Zhebei Pharmaceutical Co., Ltd. - Original Registrant

Classifications

5 Drugs for medical purposes, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Drugs for medical purposes, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Drugs for medical purposes, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Drugs for medical purposes, namely, anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Drugs for medical purposes, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antibiotics; Drugs for medical purposes, namely, adjuvant treatment of acute and chronic hepatitis; Pharmaceutical preparations, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Pharmaceutical preparations, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Pharmaceutical preparations, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Pharmaceutical preparations, namely, anticancer for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Pharmaceutical preparations, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Pharmaceutical preparations, namely, adjuvant treatment of acute and chronic hepatitis; Antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia

The mark consists of a circle surrounding stylized clouds, bamboo trees, and mountains. Below the circle are Chinese characters above the wording "MOGANSHAN" in stylized text.
The non-Latin characters in the mark transliterate to "MO GAN SHAN" and this means "Mount Mogan" in English.
"MOGANSHAN" AND THE CHINESE CHARACTERS IN THE MARK THAT TRANSLITERATE TO "MO GAN SHAN"

Trademark Events

Mar 19, 2024

Notice Of Registration Confirmation Emailed

Mar 19, 2024

Registered-Principal Register

Jan 7, 2024

Notification Of Possible Opposition - Processed By Ib

Jan 2, 2024

Notification Processed By Ib

Jan 2, 2024

Official Gazette Publication Confirmation E-Mailed

Jan 2, 2024

Published For Opposition

Dec 20, 2023

Notification Of Possible Opposition Sent To Ib

Dec 20, 2023

Notification Of Possible Opposition Created, To Be Sent To Ib

Dec 13, 2023

Notification Of Possible Opposition Sent To Ib

Dec 13, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Dec 13, 2023

Notification Of Notice Of Publication E-Mailed

Nov 22, 2023

Approved For Pub - Principal Register

Nov 16, 2023

Examiner's Amendment Entered

Nov 16, 2023

Notification Of Examiners Amendment E-Mailed

Nov 16, 2023

Examiners Amendment E-Mailed

Nov 16, 2023

Examiners Amendment -Written

Nov 10, 2023

Examiner's Amendment Entered

Nov 10, 2023

Notification Of Examiners Amendment E-Mailed

Nov 10, 2023

Examiners Amendment E-Mailed

Nov 10, 2023

Examiners Amendment -Written

Oct 26, 2023

Teas/Email Correspondence Entered

Oct 26, 2023

Correspondence Received In Law Office

Oct 26, 2023

Teas Response To Office Action Received

Jun 18, 2023

Refusal Processed By Ib

May 31, 2023

Non-Final Action Mailed - Refusal Sent To Ib

May 31, 2023

Refusal Processed By Mpu

Apr 1, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Mar 31, 2023

Non-Final Action Written

Mar 27, 2023

Assigned To Examiner

Jul 19, 2022

Application Filing Receipt Mailed

Jul 15, 2022

New Application Office Supplied Data Entered

Jul 14, 2022

Sn Assigned For Sect 66a Appl From Ib